Gain Therapeutics, Inc.

NasdaqGM GANX

Gain Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2024: USD -21.37 M

Gain Therapeutics, Inc. EBITDA is USD -21.37 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 4.49% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Gain Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -22.37 M, a -36.22% change year over year.
Gain Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -16.42 M, a -34.68% change year over year.
Gain Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -12.19 M, a -377.96% change year over year.
Gain Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -2.55 M.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqGM: GANX

Gain Therapeutics, Inc.

CEO	Mr. Gene Mack M.B.A.
IPO Date	March 19, 2021
Location	United States
Headquarters	4800 Montgomery Lane
Employees	29
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Key trends

Past 5 years